A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer

被引:26
作者
Delfino, FJ [1 ]
Stevenson, H [1 ]
Smithgall, TE [1 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA
关键词
D O I
10.1074/jbc.M507331200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The human c-fes locus encodes a non-receptor protein-tyrosine kinase implicated in myeloid, vascular endothelial, and neuronal cell differentiation. A recent analysis of the tyrosine kinome in colorectal cancer identified c-fes as one of only seven genes with consistent kinase domain mutations. Although four mutations were identified (M704V, R706Q, V743M, S759F), the consequences of these mutations on Fes kinase activity were not explored. To address this issue, Fes mutants with these substitutions were co-expressed with STAT3 in human 293T cells. Surprisingly, the M704V, R706Q, and V743M mutations substantially reduced Fes autophosphorylation and STAT3 Tyr-705 phosphorylation compared with wild-type Fes, whereas S759F had little effect. These mutations had a similar impact on Fes kinase activity in a yeast expression system, suggesting that they inhibit Fes by affecting kinase domain structure. We have also demonstrated for the first time that endogenous Fes is strongly expressed at the base of colonic crypts where it co-localizes with epithelial cells positive for the progenitor cell marker Musashi-1. In contrast to normal colonic epithelium, Fes expression was reduced or absent in colon tumor sections from most individuals. Fes protein levels were also low or absent in a panel of human colorectal cancer cell lines, including HT-29 and HCT 116 cells. Introduction of Fes into these lines with a recombinant retrovirus suppressed their growth in soft agar. Together, our findings strongly implicate the c-Fes protein-tyrosine kinase as a tumor suppressor rather than a dominant oncogene in colorectal cancer.
引用
收藏
页码:8829 / 8835
页数:7
相关论文
共 45 条
[1]   Mutational analysis of the tyrosine kinome in colorectal cancers [J].
Bardelli, A ;
Parsons, DW ;
Silliman, N ;
Ptak, J ;
Szabo, S ;
Saha, S ;
Markowitz, S ;
Willson, JKV ;
Parmigiani, G ;
Kinzler, KW ;
Vogelstein, B ;
Velculescu, VE .
SCIENCE, 2003, 300 (5621) :949-949
[2]   Tyrosine kinase receptors as attractive targets of cancer therapy [J].
Bennasroune, A ;
Gardin, A ;
Aunis, D ;
Crémel, G ;
Hubert, P .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 50 (01) :23-38
[3]   Stem cell in gastrointestinal structure and neoplastic development [J].
Brittan, M ;
Wright, NA .
GUT, 2004, 53 (06) :899-910
[4]   The gastrointestinal stem cell [J].
Brittan, M ;
Wright, NA .
CELL PROLIFERATION, 2004, 37 (01) :35-53
[5]  
CARE A, 1994, ONCOGENE, V9, P739
[6]  
Cheng HY, 1999, MOL CELL BIOL, V19, P8335
[7]   A point mutation in the N-terminal coiled-coil domain releases c-Fes tyrosine kinase activity and survival signaling in myeloid leukemia cells [J].
Cheng, HY ;
Schiavone, AP ;
Smithgall, TE .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (18) :6170-6180
[8]   Mutation of a highly conserved aspartate residue in subdomain IX abolishes Fer protein-tyrosine kinase activity [J].
Cole, LA ;
Zirngibl, R ;
Craig, AWB ;
Jia, Z ;
Greer, P .
PROTEIN ENGINEERING, 1999, 12 (02) :155-162
[9]   Genetic predisposition to colorectal cancer [J].
de la Chapelle, A .
NATURE REVIEWS CANCER, 2004, 4 (10) :769-780
[10]   Genetic and epigenetic alterations in colon cancer [J].
Grady, WM ;
Markowitz, SD .
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, 2002, 3 :101-128